R&D Department, Cadila Pharmaceuticals Limited, Ahmedabad, India
*Corresponding Author: Bakulesh Khamar, R&D Department, Cadila Pharmaceuticals Limited, Ahmedabad, India.
Received: June 18, 2018; Published: July 11, 2018
Citation: Bakulesh Khamar. “Resistance to PD1/PD-L1 Blockade". Acta Scientific Cancer Biology 2.6 (2018).
Monoclonal antibodies targeting PD-1/PD-L1 as a monotherapy are useful in varieties of tumors to provide durable response not seen with other therapies. However large majority patients do not respond. The major reason for lack of response is lack of inflammation. Even in tumors with inflammation other defects in cancer immune cycle are responsible for lack of response. Changes in cancer immune cycle are also seen at the time of relapse in those who responded to therapy initially. In this article current information about resistance mechanisms to anti PD-1/PD-L2 therapy are reviewed.
Keywords: PD-1; PD-L1; Primary Resistance; Acquired Resistance; Resistance Mechanism CD8 Cells; T Cells; Cancer Immune Phenotype; Check Point Inhibitors
Copyright: © 2018 Bakulesh Khamar. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.